Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Author(s):

Mark Robson ◽

Seock-Ah Im ◽

Elżbieta Senkus ◽

Binghe Xu ◽

Susan Domchek ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz012 ◽

2019 ◽

Vol 30 (4) ◽

pp. 558-566 ◽

Cited By ~ 89

Author(s):

M.E. Robson ◽

N. Tung ◽

P. Conte ◽

S.-A. Im ◽

E. Senkus ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Case Medical Research ◽

10.31525/ct1-nct04296370 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Brca Mutation ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Chemotherapy Treatment ◽

EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physician’s choice (TPC) in OlympiAD.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1045 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1045-1045 ◽

Author(s):

Mark E. Robson ◽

Kathryn Jean Ruddy ◽

Seock-Ah Im ◽

Elzbieta Senkus-Konefka ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Eortc Qlq C30 ◽

Germline Brca Mutation ◽

Eortc Qlq

Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1052 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1052-1052 ◽

Cited By ~ 2

Author(s):

Nadine M. Tung ◽

Seock-Ah Im ◽

Elzbieta Senkus-Konefka ◽

Binghe Xu ◽

Susan M. Domchek ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Visceral Metastases ◽

OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice

Annals of Oncology ◽

10.1093/annonc/mdx365.006 ◽

2017 ◽

Vol 28 ◽

pp. v77 ◽

Author(s):

S. Delaloge ◽

P.F. Conte ◽

S-A. Im ◽

E. Senkus-Konefka ◽

B. Xu ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Single Agent ◽

Metastatic Breast ◽

Chemotherapy Treatment ◽

Germline Brca Mutation ◽

Single Agent Chemotherapy

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

New England Journal of Medicine ◽

10.1056/nejmx170012 ◽

2017 ◽

Vol 377 (17) ◽

pp. 1700-1700 ◽

Cited By ~ 6

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽

Abstract OT1-1-14: A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)

10.1158/1538-7445.sabcs14-ot1-1-14 ◽

2015 ◽

Author(s):

Nicholas C Turner ◽

Judith Balmana ◽

Susan M Domchek ◽

Frances Visco ◽

Charlie Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Brca Mutation ◽

Parp Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1108 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1108-TPS1108 ◽

Author(s):

Nicholas C. Turner ◽

Judith Balmaña ◽

Peter A. Fasching ◽

Sara A. Hurvitz ◽

Melinda L. Telli ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Parp Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

European Journal of Cancer ◽

10.1016/j.ejca.2019.06.023 ◽

2019 ◽

Vol 120 ◽

pp. 20-30 ◽

Cited By ~ 6

Author(s):

Mark Robson ◽

Kathryn J. Ruddy ◽

Seock-Ah IM ◽

Elżbieta Senkus ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Patient Reported Outcomes ◽

Brca Mutation ◽

Metastatic Breast ◽

Patient Reported ◽

Faculty Opinions recommendation of Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727687763.793559064 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Metastatic Breast ◽